Current News

Recently published in the Journal of Cerebral Blood and Metabolism, the article entitled “Physical therapy exerts sub-additive and suppressive effects on intracerebral neural stem cell implantation in a rat model of stroke” investigates how physical therapy affects neural stem cells implanted into stroke damage. McGowan Institute for Regenerative Medicine affiliated faculty members and collaborative authors on this work are Michael Modo, PhD, Professor in the Department of Radiology at the University of Pittsburgh, and Fabrisia Ambrosio, PhD, MPT, Director of Rehabilitation for UPMC International and an Associate Professor in the Department of Physical Medicine & Rehabilitation at the University of Pittsburgh. Read More

Positive acute and long-term interim results from the first 500 pulmonary embolism (“PE”) patients enrolled in the FlowTriever Outcomes Registry (“FLASH”) were presented at TCT 2021 by Principal Investigator, Catalin Toma, MD, an Interventional Cardiologist at University of Pittsburgh Medical Center (UPMC) and an affiliated faculty member of the McGowan Institute for Regenerative Medicine. Read More

McGowan Institute for Regenerative Medicine affiliated faculty member Michael Lotze, MD, was honored with the 2021 Society for Immunotherapy of Cancer (SITC) Lifetime Achievement Award at the SITC 36th Annual Meeting, Nov. 10-14, in Washington D.C. SITC is a member-driven organization dedicated to improving cancer patient outcomes by advancing the science and application of cancer immunotherapy through educational programs that foster scientific exchange and collaboration. Read More

When a child has cancer, their parents are rightfully focused on a cure. But that cure can come at a future cost: infertility. Read More

Over $1.6 million has been received from the NIH’s National Heart, Lung, and Blood Institute (NHLBI) for the 5-year Cardiothoracic Surgery Research Training Program. This research training grant is focused on the next generation of academic cardiac and thoracic surgeons and will be led by the following team which includes four McGowan Institute for Regenerative Medicine affiliated faculty members: Read More

LyGenesis is a clinical-stage biotechnology company whose cell therapies use patients’ lymph nodes as bioreactors to regrow functioning ectopic organs. LyGenesis’s lead allogeneic cell therapy program is currently in a Phase 2a clinical trial for patients with end stage liver disease. LyGenesis was built on nearly a decade of groundbreaking academic research by McGowan Institute for Regenerative Medicine faculty member Eric Lagasse, PharmD, PhD, Associate Professor in the Department of Pathology at the University of Pittsburgh and LyGenesis Founder and Chief Scientific Officer. Read More

Maddie Cramer, a doctoral student in the Bioengineering Department at the University of Pittsburgh and a team member in the laboratory of Stephen Badylak, DVM, PhD, MD, will receive the Outstanding Student Award from TERMIS-AA. Dr. Badylak is a deputy director of the McGowan Institute for Regenerative Medicine, professor in the Department of Surgery, and director of the Center for Pre-Clinical Tissue Engineering within the Institute. Read More

During the Magee-Womens Summit, the Magee-Womens Research Institute (MWRI) awarded the $1 million Magee Prize to an international team led by McGowan Institute for Regenerative Medicine affiliated faculty member Pamela Moalli, MD, PhD, director of urogynecology and pelvic reconstruction surgery at UPMC Magee-Womens Hospital and MWRI. The team is working to develop new biomaterials to repair tissue loss in women with compromised vaginal structure and function. Read More

A great need currently exists for medical devices designed specifically for children.

Pediatric Device Innovators Forum (PDIF) is a recurring collaborative educational experience designed to connect and foster synergy among innovators across the technology development ecosystem who are interested in pediatric medical device development. Read More

ALung Technologies, Inc., the leading provider of low-flow extracorporeal carbon dioxide removal (ECCO2R) technologies for treating patients with acute respiratory failure, announced that the Food and Drug Administration (FDA) has granted the company De Novo clearance for the Hemolung Respiratory Assist System. This system was developed  at the McGowan Institute for Regenerative Medicine by a team of researchers led by faculty member William Federspiel, PhD, the company’s cofounder and professor of bioengineering, chemical engineering, critical care medicine, and the Clinical Translation Institute at the University of Pittsburgh. Dr. Federspiel is also the director of the Medical Devices Laboratory at the McGowan Institute. Read More